Pneumonia Therapeutics Market Analysis

Pneumonia Therapeutics Market Analysis

Increasing number of on-going clinical trials for the development of drug molecules will have a significant impact on the market progression. Currently, different companies operating in the pneumonia therapeutics market including Merck and GSK are putting enormous efforts in the research and development activities. For instance, in February 2020, FDA accepted the review supplemental new drug application for Recarbrio for the treatment of adults with ventilator-associated and hospital-acquired bacterial pneumonia. Introduction of such new drug molecules into will augment the market growth over the forecast timeframe. However, low treatment rates in developing economies as compared to developed may restrict the market growth over analysis timeframe.

Antiviral drugs market segment will witness around 7.5% CAGR during the forecast period. Viral pneumonia spreads through fluid present in the air droplets after an individual coughs or sneezes. These fluids enter into the body through mouth or nose. Several treatment options including oseltamivir and acyclovir among others are used to treat the antiviral infection. Similarly, these drugs help to minimize the severity of flu virus spreading into the body that further augments the market progression.
 

According to American Thoracic Society 2019, viral pneumonia is the one of the leading cause of hospitalization among infants in the U.S. and rest of the world. Thus, rising prevalence of viral pneumonia drives the demand for pneumonia therapeutics drug.
 

The geriatric segment accounted for around 20% market share in 2019 and is estimated to rise over the forecast period. Geriatric individuals are susceptible to pneumonia due to weak immune system. Diabetes, heart disease and other serious illness are very common in elderly individuals that eventually increases the risk of pneumonia. Furthermore, geriatric population base has greater chances of getting affected by flu as well as other lung-related disorders, that sometimes often develop into pneumonia.
 

HAP market accounted for more than USD 352 Mn in 2019. Hospital-acquired pneumonia is a lung infection that occurs during hospital stays. Majority of patients with hospital-acquired pneumonia develop serious complications that include renal failure, respiratory failure and empyema due to severe and weak health conditions. Therefore, increasing incidences of hospital-acquired pneumonia will surge the demand for pneumonia therapeutics drugs.
 

The online pharmacies market will exhibit around 8% CAGR during the forecast timeframe. Online pharmacies offer better pricing than offline stores with low product and transaction costs. Additionally, online pharmacies offer convenience and accessibility to people with limited mobility. Furthermore, these pharmacies provide doorstep delivery within a short period of time that increases their preference. Aforementioned factors will stimulate the pneumonia therapeutics industry growth during forecast timeframe.
 

Asia Pacific pneumonia therapeutics market held considerable revenue share in 2019 and accounted for more than 34% market share. Increasing prevalence of pneumococcal disease leading to weak immune systems will surge the demand for pneumonia therapeutics drugs. Furthermore, introduction of pneumonia related programs to control the prevalence of pneumonia in this region will favour the market growth. Thus, increasing number of favorable government initiatives will escalate the market demand over the forecast period.